Publications

Identification of Debio 0432 as a potent and selective USP1 Inhibitor for Cancer Therapy

Anti-Tumor Activity of Debio 0123 in Combination with Sacituzumab Govitecan in Preclinical Models of Breast Cancer

A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a…

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase…

Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX

Deploying the Genedata Profiler Platform for Value Creation in Debiopharm’s Drug Development Process

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Debio 0123, a selective, brain penetrant WEE1 inhibitor in clinical development for patients with solid tumors

Debio 1562M, a next generation Antibody Drug Conjugate (ADC) targeting CD37 for AML and MDS treatment